Ms. Hunt brings over 25 years of drug development experience to Opus, with specific expertise in global clinical operations, product development and program management in biologics, small molecules, gene editing and gene therapy. Prior to joining Opus, she held key clinical and regulatory positions at several biopharmaceutical companies, including Genzyme, Voyager Therapeutics and Editas Medicine. While at Editas, she oversaw the development of CRISPR medicines across ophthalmology, hemoglobinopathies and oncology, including Editas’ gene therapy to restore vision loss in patients with LCA type 10, the first in-vivo CRISPR IND ever accepted by the U.S. Food and Drug Administration. Ms. Hunt earned a B.S. in Biology from State University of New York College of Environmental Science and Forestry at Syracuse and a M.S. in Management from Lesley University.